Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,324 across all filing types
Latest filing 2024-02-21 Earnings Release
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Results for the fourth quarter of 2023
Earnings Release Classification · 98% confidence The document is titled 'Photocure ASA: Results for the fourth quarter of 2023' and provides detailed financial metrics (revenues, EBITDA, EBIT) for Q4 2023, along with forward-looking guidance for 2024. This content strongly indicates a periodic financial results announcement. The text explicitly mentions key financial figures and business updates, which aligns with an Earnings Release (ER). Although it mentions 'full financial report and presentation enclosed' and that the 'quarterly report and presentation will be published,' the provided text itself is the summary announcement containing the core results and management commentary, making it an Earnings Release (ER) rather than just a Report Publication Announcement (RPA) or a comprehensive Interim Report (IR), as it focuses on the immediate results release. Q4 2023
2024-02-21 English
Photocure ASA: Results for the fourth quarter of 2023
Earnings Release Classification · 99% confidence The document is titled "Photocure ASA: Results for the fourth quarter of 2023" and contains detailed financial metrics (revenues, EBITDA, EBIT) for Q4 2023 compared to Q4 2022, along with forward-looking guidance for 2024. This content strongly indicates a periodic financial results announcement. Since it covers a specific quarter (Q4) and is not the full annual report (10-K), it fits the definition of an Interim/Quarterly Report (IR). Although it contains highlights typical of an Earnings Release (ER), the depth of financial figures and the mention of the full financial report being enclosed suggest it is the comprehensive quarterly report itself, rather than just the initial press release highlights. The document explicitly mentions the 'quarterly report and presentation' will be published, but the text provided *is* the substance of the results announcement, making IR the most appropriate classification for the comprehensive period results. Q4 2023
2024-02-21 English
Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results
Report Publication Announcement Classification · 98% confidence The document is an invitation from Photocure ASA announcing the upcoming release of their '4th quarter and preliminary full year 2023 financial results' on February 21, 2024, followed by a live investor presentation/webcast. It explicitly states that the 'quarterly report and presentation will be published at 08:00 CET' and provides details for the subsequent presentation. Since the document itself is an announcement about the publication of financial results and the associated presentation, and it is very short (2249 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the full Earnings Release (ER) or Interim Report (IR) itself. It is announcing the release of those reports.
2024-02-19 English
Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results
Report Publication Announcement Classification · 98% confidence The document is an invitation announcing when Photocure ASA will release its 4th quarter and preliminary full year 2023 financial results (on Feb 21, 2024, at 08:00 CET) and when the subsequent investor presentation/webcast will occur (at 14:00 CET). It explicitly states that the 'quarterly report and presentation will be published at 08:00 CET' and provides details for the live stream. Since the document itself is an announcement about the publication of financial results and the associated presentation, and given its short length (2457 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the full Earnings Release (ER) or Interim Report (IR) itself. It is announcing the release of those reports.
2024-02-19 English
Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024
Regulatory Filings Classification · 98% confidence The document is a press release from Photocure ASA dated January 29, 2024, announcing that its partner, Asieris, presented clinical trial and real-world data for Hexvix at the ASCO GU 2024 symposium. This content details scientific findings, partnership updates, and general company news, rather than being a formal regulatory filing like a 10-K, a quarterly report (IR), or a specific financial announcement (like DIV or CAP). It is an announcement of information dissemination, but it is not explicitly announcing the *publication* of a formal report (which would suggest RPA). Since it contains significant operational and scientific updates, and does not fit the definitions for ER, IR, 10-K, or specific financial events, it falls best under the general category for corporate announcements that are not strictly regulatory filings or financial results releases. Given the options, this type of press release announcing scientific data presentation is often categorized as a general Regulatory Filing (RNS) if a more specific category like 'Investor Presentation' (IP) or 'Earnings Release' (ER) does not apply. Since it is a press release detailing scientific progress and partnership milestones, and not a formal financial report, RNS is the most appropriate fallback for a general corporate announcement not covered elsewhere.
2024-01-29 English
Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024
Regulatory Filings Classification · 95% confidence The document is a press release from Photocure ASA announcing that its partner, Asieris, presented clinical trial and real-world data for the drug Hexvix at the ASCO GU 2024 symposium. This type of announcement, detailing scientific or operational updates via a press release format, typically falls under general Investor Relations or Regulatory Filings. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), and it is an announcement of scientific data presentation rather than a formal regulatory filing like a DVA or LTR, the most appropriate classification is Regulatory Filings (RNS) as a general announcement, or potentially Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the context of a press release detailing partner activities and clinical data, RNS serves as the best fit for a general corporate/scientific update that doesn't match a more specific category like ER or MDA.
2024-01-29 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.